Regen BioPharma Inc (RGBP) Q3 2024 Earnings Report

Regen BioPharma (RGBP) reported QQ3 2024 results that underscore the company’s status as an early-stage biotechnology company with limited near-term revenue and ongoing cash burn. Revenue for the quarter was $59,065 with gross profit of $59,065, producing an implied gross margin of 100% in the reported line item, though the quarterly data for cost of revenue was not consistently disclosed and is uneven across periods. The company posted a significant operating loss of $107.97 million? No, $107,966 in operating income loss and a net loss of $117,108 in the quarter, with EBITDA of $(108,227). Net income margin stood at approximately (1.98%). YoY revenue growth is reported as modest at 0.59% with flat QoQ revenue (0.00%). However, the quarterly figures reflect substantial operating spending: Research and Development $32,500 (Q3 2024), SG&A plus Selling/General & Administrative $134,531, and total operating expenses of $167,031. Cash burn remains a critical concern: cash flow from operations was $(172,589), and free cash flow was also approximately $(172,590); cash at period-end was $61,849, against rolling liabilities of $5.33 million and substantial deferred revenue of $1.50 million. The balance sheet shows negative stockholders’ equity of $(5.16) million and total liabilities of $5.33 million, signaling meaningful balance sheet fragility unless offset by new financing or meaningful revenue recognition. The liquidity metrics are extremely tight (current ratio and quick ratio both around 0.029x). These dynamics imply a fragile liquidity runway and elevated dilution risk if financing is required to sustain operations.